“If you're thinking about urology, then what I would do is get exposure as early as possible,” says Curtis A. Pettaway, MD.
In this video, Society of Urologic Oncology’s 2021 Huggins Medalrecipient, Curtis A. Pettaway, MD, advises medical students and young urologists on navigating the field. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.